Full speed ahead – New Celsius42
After 4 months and many hours of work by our creative team, we look forward to publishing our new company website in the near future. “This innovation represents a true milestone for the development of Celsius42,” says Christian Hartmann, the company’s new CEO. “In addition to the remake of our corporate identity, there are many ongoing activities associated with our product range,” he adds. “We are currently working on our vision up to the year 2025. Our company will present many innovations and product enhancements at the MEDICA tradeshow in Düsseldorf this year and over the course of the coming years.”
Parallel to product and market development, the company’s priorities for the coming months and years naturally also include global expansion. Moreover, technical and scientific cooperation will be at the core of this growth strategy.
We invite you to visit us at ESHO in Berlin from May 16-19 to learn more about our innovations in direct conversations. We look forward to your visit.
Our communication channels will keep you updated about the further activities of our company.
Your Celsius42 Team
The TCS – Tumor Cell Solution by Celsius42.
Everyone is unique. Diseases don’t follow a standardized pattern, so stereotype thinking is not an option, especially with cancer. The tumor type and location, the patient’s physical condition, mental state and pre-existing conditions are just some of the factors that play a role. Responding to this individuality was the objective of developing the TCS – Tumor Cell Solution for Celsius42.
Our engineers and developers have learned everything they know about hyperthermia from it. In Eschweiler, we explore the body’s own processes and transform them into innovative medical technology.
Innovative medical technology is designed to reduce suffering and speed up recovery. To us at Celsius42, that means thinking about people first and about technology second. Our technology works gently and effectively in tune with the body’s own processes.
Take the example of the hyperthermia system TCS – Tumor Cell Solution.
Tel. +49 2403 7829 230
Contact for your qustions, Christian Hartmann
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Full speed ahead – New Celsius42 here
News-ID: 1035641 • Views: 564
More Releases for Eschweiler
Blood Metabolites Market Research Provides an In-Depth Analysis on the Future Gr …
The recent research report published by Market Expertz on the Global Blood Metabolites Market renders the latest information and valuable insights to the readers to help them capitalize on the growth opportunities that will surface in the forecast duration. The market intelligence report gives a comprehensive analysis of the Global Blood Metabolites Market and includes a detailed investigation of the market, historical analysis of the information gathered from the years
Blood Metabolites Market to Witness Huge Growth by 2023 | Leading Key Players: C …
The qualitative research study conducted by HTF MI titled “Global Blood Metabolites Industry Market Research Report” provides primary Data, surveys, Scope of the Product and vendor briefings. The market dynamic forces have been determined after conducting a detailed study of the Global Blood Metabolites market. The study provides forecasts for Blood Metabolites investments till 2022. If you are involved in the Blood Metabolites industry or intend to be, then this study